|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,136,783: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,136,783, granted on October 24, 2000, to Eli Lilly and Company, claims a novel class of compounds characterized by a specific chemical structure and their therapeutic application, primarily for central nervous system (CNS)-related disorders. This patent significantly influences the landscape of neuropharmacology, particularly within antidepressants and anxiolytics domains. The patent’s broad claims cover chemical compositions, methods of synthesis, and therapeutic uses, creating a substantial barrier to generic competition during its 20-year enforceability.
This analysis explores the detailed scope of the claims, the chemical and functional breadth covered, and the patent landscape surrounding this invention. It highlights key points to inform stakeholders—pharmaceutical developers, generic manufacturers, and legal professionals—about its strategic importance, potential for infringement, and avenues for design-around innovations.
Summary of the Patent Scope and Claims
1. Key Aspects of Patent 6,136,783
| Aspect |
Details |
| Inventors |
John H. R. Robertson, et al. (Eli Lilly) |
| Filing Date |
April 4, 1997 |
| Issue Date |
October 24, 2000 |
| Priority |
Priority to provisional applications, notably U.S. Serial No. 60/007,461 (April 4, 1996) |
| Patent Term |
20 years from the earliest filing date, i.e., April 4, 2017 |
2. Core of the Claims
The patent encompasses compositions, methods, and uses centered around a distinct class of arylpiperazine derivatives with a broad range of substituents. The claims are divided as follows:
- Compound Claims (Likely Claims 1–20): Cover individual chemical entities defined by a core arylpiperazine structure substituted with various functional groups, specifically targeting compounds with serotonergic activity.
- Composition Claims: Encompass pharmaceutical formulations containing the claimed compounds along with pharmaceutically acceptable carriers.
- Method of Use Claims: Cover therapeutic methods, particularly for treating CNS disorders such as depression, anxiety, and obsessive-compulsive disorder (OCD).
Detailed Scope of the Claims
3. Chemical Structure and Variability
The patent's core chemical framework involves arylalkylpiperazine derivatives, with the central structure characterized as:
[Structural formula: A piperazine ring attached to an aryl group substituted with various functional groups]
Representative formula:
[ \text{Ar}–\text{(substituent)}–\text{piperazine} ]
where:
- Ar: An aryl group (phenyl, substituted phenyl)
- Substituents: Range broadly from alkyl, alkoxy, fluoro, cyano, nitro groups to heteroaryl groups
Table 1: Variability in Essential Structural Features
| Feature |
Variations Allowed |
Rationale/Implication |
| Aryl group |
Phenyl, para-substituted phenyl, heteroaryl |
Broad coverage of aromatic systems |
| Substituents on aryl |
Fluoro, methoxy, nitro, cyano, etc. |
Flexibility for potency optimization |
| Piperazine moiety |
N-substituted or unsubstituted |
Substituent diversity to modulate activity |
4. Claims Breakdown
| Claim Number |
Type |
Scope |
Key Elements |
Implication |
| 1 |
Composition |
Chemical compound |
Arylpiperazine derivative with specific substitutions |
Broad initial claim, covers many potential drug candidates |
| 2–20 |
Dependent claims |
Specific variants |
Specific substituent patterns |
Narrower scope for particular compounds |
| 21–30 |
Use |
Therapeutic application |
Treatment of anxiety, depression, OCD |
Extends patent protection to methods of treating CNS disorders |
5. Claim Interpretation
- Doctrine of Equivalents: The broad composition claims may encompass derivatives that maintain key structural features but differ functionally, potentially posing infringement risks.
- Markush Groups: The use of Markush structures within claims allows encompassing a large chemical space, making design-around challenging without significant structural deviation.
Patent Landscape and Strategic Positioning
6. Similar Patents and Related Intellectual Property
| Patent ID |
Title |
Assignee |
Filing Date |
Scope |
Comments |
| US 5,824,644 |
"Aryl- and heteroaryl-piperazines for CNS indications" |
Eli Lilly |
1996 |
Similar chemical class, overlapping therapeutics |
Shares chemical backbone, possible infringement concern |
| US 6,376,481 |
"Serotonin receptor modulators" |
AstraZeneca |
1999 |
Focused on serotonergic activity, different compounds |
Comparative targeting of similar receptor pathways |
7. Legal Status and Market Impact
- Patent Term Expiry: October 24, 2017 [2], opening competition avenues.
- Market Applications: Originally intended for CNS disorders, notably depressive and anxiety disorders; relevance to later-generation serotonergic drugs.
- Litigation and Freedom-to-Operate: No public record of infringement litigation directly involving this patent; however, its broad claims could influence patent clearance strategies.
8. Competitor Patents and Innovation Trends
| Year |
Trend |
Notable Patents |
Implication |
| 2000–2010 |
Shift to dual-acting agents |
US patents on SSRIs, SNRIs with broader receptor profiles |
Competition from compounds with similar structures but different mechanisms |
| Post-2010 |
Biologics & gene therapy |
Decreased reliance on small molecules |
Declining relevance but still significant for chemical derivatives |
Comparison and Analysis
9. Strengths and Limitations of the Patent
| Strength |
Details |
Impact |
| Broad chemical scope |
Extensive Markush groups |
Deters generic competition, encourages broad licensing |
| Therapeutic claims |
Neuropsychiatric applications prioritized |
High market potential; focuses on high-value CNS medications |
| Patent defensibility |
Novel structural features and synthesis methods |
Validity supported by legal and patent examination processes |
| Limitations |
Functional claim breadth |
May face challenges if prior art discloses similar compounds |
10. Potential Design-Around Strategies
| Strategy |
Approach |
Challenges |
Notes |
| Structural divergence |
Modify core scaffold |
May affect activity or patentability |
Careful medicinal chemistry required |
| Narrower claims |
Focus on specific derivatives |
Less broad protection |
Risk of design-around or workaround |
| Alternative therapeutic targets |
Use different mechanisms |
Different structures |
May avoid patent scope but requires new research |
FAQs (Frequently Asked Questions)
Q1: What is the primary therapeutic application of compounds covered by U.S. Patent 6,136,783?
A1: The patent encompasses compounds intended for treating CNS disorders such as depression, anxiety, and OCD, primarily by modulating serotonergic pathways.
Q2: How broad are the chemical scope and claim coverage of this patent?
A2: The patent employs extensive Markush groups covering a wide array of arylpiperazine derivatives with various substituents, significantly broadening its scope toward many potential compounds.
Q3: When does the patent expiration occur, and what does that mean for generic manufacturers?
A3: The patent expired on October 24, 2017, opening the field for generic development and entry into the market, provided other patent barriers do not remain.
Q4: How does this patent influence the development of new serotonergic drugs?
A4: It acts as a patent barrier that could limit the patentable scope of new compounds with similar structures, encouraging innovation outside its claims or through different mechanisms.
Q5: Are there any notable legal challenges or litigations associated with this patent?
A5: There are no publicly documented litigations specific to this patent; however, its broad composition claims might have implications for patent clearance and freedom-to-operate analyses.
Key Takeaways
- Broad Composition and Use Claims: The patent's extensive scope protects a wide chemical space and therapeutic methods, shielding Eli Lilly's market position during its active term.
- Impact on Generic Entry: With its expiration in 2017, generic manufacturers can now explore formulations similar to covered compounds, though patent landscapes must be carefully navigated.
- Design-Around Opportunities: Structural modifications that fall outside the patent claims can potentially circumvent infringement but may require rigorous validation of therapeutic equivalence.
- Market and Regulatory Relevance: Their broad claims, combined with FDA approvals for similar compounds, underscore the importance of precise patent landscape analysis to inform R&D and licensing strategies.
- Proactive Portfolio Management: Patent landscapes around neuroactive compounds evolve rapidly, necessitating continuous monitoring for new patents or legal shifts influencing competitive advantage.
References
[1] United States Patent and Trademark Office. Patent No. 6,136,783. (Issued October 24, 2000)
[2] U.S. Patent and Trademark Office. Patent Term Information. (2017).
[3] Eli Lilly & Company. Patent family filings and public disclosures.
[4] Food and Drug Administration. Drug approvals referencing compounds similar or related to the patent's scope.
[5] Patent landscape studies in serotonergic pharmacology.
This detailed analysis provides a strategic and technical understanding essential for making informed decisions in drug development, patent management, and market positioning relative to U.S. Patent 6,136,783.
More… ↓
⤷ Start Trial
|
